CTMX Q3 2021 Earnings — CytomX Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CTMXCytomX Therapeutics, Inc.

$822M

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$18M-1.1% YoY

Gross Profit

$18M100.0% margin

Operating Income

-$23M-128.7% margin

Net Income

-$23M-128.4% margin

EPS (Diluted)

$-0.35

QoQ Revenue Growth

+8.0%

Cash Flow

Operating Cash Flow

-$30M

Free Cash Flow

-$30M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$371M

Total Liabilities

$260M

Stockholders' Equity

$112M

Cash & Equivalents

$236M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$18M	$18M	-1.1%
Gross Profit	$18M	$18M	-1.1%
Operating Income	-$23M	-$15M	-52.0%
Net Income	-$23M	-$15M	-53.5%